Fig. 3.

Treatment with eRAPA and moxifloxacin during acute Mtb infection modulates lung immunopathology. (A) Six- to 8-week-old C3HeB/FeJ mice were infected with ∼50-100 CFUs of Mtb Erdman and then categorized into three groups (Eudragit control diet with no treatment, moxifloxacin plus Eudragit and moxifloxacin plus eRAPA). These mice were treated for 4 weeks starting week 4 post infection until week 8, and then euthanized. Bacterial burden in the lungs and spleen was determined. (B) Levels of IFNγ were evaluated in filtered cell-free lysates using multiplex MSD. (C) Multilobe lung histopathological analysis was conducted, and necrotic granulomas are marked with a blue asterisk. (D) Total lung area under infection-induced inflammation was also determined. Each group included 5 or 6 mice. Data are means±s.e. Statistical significance was calculated using either an unpaired, two-tailed Student's t-test (two groups), one-way ANOVA (three groups) with Bonferroni's correction or one-way ANOVA with Kruskal–Wallis test (*P<0.5; ***P<0.005; ****P<0.0005; ns, not significant). Scale bars: 5 mm (C, M1, M3, M4 bottom, M5 bottom and M6); 4 mm (C, M2, M4 top and M5 top).